Predictors of severe hematotoxicity after CAR T-cell therapy.

Emily C. Liang(Fred Hutch Cancer Center), Jordan Gauthier(Seattle Cancer Care Alliance), Rahul Banerjee(University of Washington), Andrew J. Cowan(University of Washington Medical Center), Aiko Torkelson(Fred Hutch Cancer Center), Andrew J. Portuguese(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Noam E. Kopmar(University of Washington), Mazyar Shadman(University of Washington), Delaney Kirchmeier(Fred Hutch Cancer Center), Christina Poh(University of Washington), Lorenzo Iovino(University of Pisa), Aya Albittar(University of Washington), Ryan D. Cassaday(University of Washington), Abigail Chutnik(Fred Hutch Cancer Center), Jennifer Jing Huang(University of Washington), Joshua A. Hill(Fred Hutch Cancer Center), Barbara Pender(Fred Hutch Cancer Center), Erik L. Kimble(University of Washington)
Journal of Clinical Oncology
June 1, 2024
10.1200/jco.2024.42.16_suppl.7024
Cited by 0

Related Papers

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
Global Burden of Multiple Myeloma
|JAMA Oncology|2018|631
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453